Stay updated on Risankizumab vs Secukinumab in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page.

Latest updates to the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe clinical trial record for a completed Phase 3 comparison of risankizumab and secukinumab for moderate-to-severe plaque psoriasis is displayed instead of an access-denied error.SummaryDifference78%

- Check16 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide banner announces NIH website updates and says the agency is transitioning its terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check30 days agoChange DetectedThe error page’s footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continued to show a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content with an access-denied message. This indicates that the study details are currently blocked from access.SummaryDifference18%

Stay in the know with updates to Risankizumab vs Secukinumab in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page.